Country: Kanada
Lingwa: Ingliż
Sors: Health Canada
L-ISOLEUCINE; L-LEUCINE; L-LYSINE (L-LYSINE ACETATE); METHIONINE; L-PHENYLALANINE; L-THREONINE; TRYPTOPHAN; L-VALINE; L-TYROSINE; L-ALANINE; L-ARGININE; GLYCINE; L-PROLINE; SERINE; HISTIDINE
HOSPIRA HEALTHCARE ULC
B05BA01
AMINO ACIDS
360MG; 470MG; 360MG; 200MG; 220MG; 260MG; 80MG; 400MG; 44MG; 640MG; 490MG; 640MG; 430MG; 210MG; 150MG
SOLUTION
L-ISOLEUCINE 360MG; L-LEUCINE 470MG; L-LYSINE (L-LYSINE ACETATE) 360MG; METHIONINE 200MG; L-PHENYLALANINE 220MG; L-THREONINE 260MG; TRYPTOPHAN 80MG; L-VALINE 400MG; L-TYROSINE 44MG; L-ALANINE 640MG; L-ARGININE 490MG; GLYCINE 640MG; L-PROLINE 430MG; SERINE 210MG; HISTIDINE 150MG
INTRAVENOUS
250ML/700ML/800ML/1000ML
Ethical
CALORIC AGENTS
Active ingredient group (AIG) number: 1550865004; AHFS:
CANCELLED POST MARKET
2016-07-29
PRESCRIBING INFORMATION AMINOSYN7 5% AMINOSYN7 7% AMINOSYN7 8.5% AMINOSYN7 10% AMINOSYN TM/MD RF INJECTION 5.2% (amino acids for injection 5%, 7%, 8.5%, 10%, and 5.2% renal formula) SULFITE-FREE NUTRITIVE SUPPLEMENT FOR INTRAVENOUS INFUSION Hospira Healthcare Corporation Date of Revision: April 11, 2012 1111 Dr. Frederik-Philips, 6 th floor St-Laurent,Quebec H4M 2X6 CONTROL NOS. 150040 AND 150041 _PRESCRIBING INFORMATION; Aminosyn® 5%, 7%, 8.5%, 10% and RF Injection 5.2% _ _Page 2 of 14 _ NAMES OF DRUGS: AMINOSYN 7 5% AMINOSYN 7 7% AMINOSYN 7 8.5% AMINOSYN 7 10% AMINOSYN TM/MD RF INJECTION 5.2% (amino acids for injection 5%, 7%, 8.5%, 10%, and 5.2% renal formula) Sulfite-Free THERAPEUTIC OR PHARMACOLOGICAL CLASSIFICATION Nutritive Supplement for Intravenous Infusion ACTION 1. PROTEIN SPARING (PERIPHERAL USE) : It has been shown that it may be preferable for short periods of time, 3 to 5 days, to mobilize fat (as in total starvation) for meeting energy requirements to spare protein. Under conditions of total fasting, lipid mobilization provides energy substrate in the form of free fatty acids and ketone bodies. Lipolysis occurs because insulin levels are low. If high concentrations of carbohydrates are administered, insulin levels will rise and inhibit lipid mobilization. With brief periods of fasting (less than 24 hours), energy requirements are usually met by glycogenolysis of the glycogen stored in the liver. However, after glycogen is depleted, lipolysis of body fat becomes the fat source of energy. Thus, when amino acids (without dextrose) are infused into a peripheral vein, lipolysis and ketogenesis occur freely and caloric requirements are met without proteolysis. This spares protein and the body's muscle mass, while providing a substrate for essential protein synthesis. Amino acid peripheral intravenous infusions result in: (1) availability of free fatty acids and ketone bodies as sources of energy, and (2) the concomitant utilization of administered amino acids for protein synthesis. 2. ADJUNCTIVE FOR TO Aqra d-dokument sħiħ